Page 226 - ebook HCC

PROGRAMME AND ABSTRACTSAND ABSTRACTS
GENEVA, SWITZERLANDA, SWITZERLAND
EASL HCC SUMMITHCC SUMMIT
224
224 PROGRAMME GENEV EASL 225
225
FEBRUARY 13 - 16, 2014Y 13 - 16, 2014
FEBRUAR

n Median OS (days) Median TTP (days) Table Legend :
a
Baseline characteristics b AFP, alpha-fetoprotein; BCLC, Barcelona Clinic Liver Cancer; CLIP, Cancer of the Liver
ECOG PS c Italian Program; ECOG PS, Eastern Cooperative Oncology Group performance status;
0 168 617 231 MELD, model for end-stage liver disease; NA, Not Assessable; TNM, tumor node metastasis.
1 84 285 184 aTTP defined as time (days) from start of sorafenib to date of first documented disease
2 20 79 125 progression (PD). Only radiologically documented PD of tumor considered as PD.
AFP, ng/mL c bAt start of therapy ; cPatients with unknown status not shown; dNon-evaluable patients
<400 179 475 211 not shown; eMELD missing (n=60);
≥400 80 358 166
Staging system b
Child-Pugh d
A 214 616 219
B 31 189 84
C 2 NA 248
BCLC d
A 33 NA 818
B 87 475 211
C 142 318 147
D 5 NA 611
MELD e
<10 136 525 231
10–<20 74 351 127
20–<30 3 NA 194
30–<40 23 662 354
NA
1
CLIP

d
CLINICAL POSTER ABSTRACTS 4–6 d 87 655 367 CLINICAL POSTER ABSTRACTS
0
156
1
2
166
332
73
316
32
3
115
189
19
295

TNM

NA
I
161
43
II
189
IIIA 24 617 150
98
365
IIIB 3 NA NA
IIIC 34 358 261
IV 52 287 126